Literature DB >> 3855265

Acute promyelocytic leukemia in 57 previously untreated patients.

C Cordonnier, J P Vernant, B Brun, M G Heilmann, M Kuentz, P Bierling, J P Farcet, M Rodet, N Duedari, M Imbert.   

Abstract

Fifty-seven patients in initial phase of acute promyelocytic leukemia (APL) were treated in the same department with heparin infusion, platelet transfusions, and two related induction regimens both including cytosine arabinoside and daunorubicin. Clinical and biological findings at presentation were studied. The complete remission (CR) rate was 53%. Twenty-seven patients (47%) died during the initial course of the disease, either before day 5 (early death [ED], n = 7) or after day 5 (death in aplasia [DA], n = 20). Most ED was due to intracerebral hemorrhage (6/7), especially when large hemorrhages had been seen on fundus oculi examination. Most DA was due to multivisceral failure (9/20). No correlation was found between initial disseminated intravascular coagulation (DIC) and death. However, the worsening of coagulation parameters during induction therapy, with or without initial DIC, significantly increased the occurrence of renal and respiratory failure which were particularly frequent during the first month. The median duration of survival was short (3.5 months) and the median duration of CR (11 months) was similar to that of other acute myeloid leukemias treated with the same regimens. The possible causes of the high mortality observed during the initial courses of APL and the possible benefit of a more graduate induction chemotherapy are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3855265     DOI: 10.1002/1097-0142(19850101)55:1<18::aid-cncr2820550104>3.0.co;2-b

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

Review 1.  [Acute central nervous symptoms in oncologic patients].

Authors:  K Orlopp; I G H Schmidt-Wolf; H Urbach; U Schlegel
Journal:  Internist (Berl)       Date:  2005-01       Impact factor: 0.743

2.  Prompt all-trans retinoic acid administration and early death in acute promyelocytic leukemia: what does the evidence say?

Authors:  A Rashidi; S I Fisher
Journal:  Leukemia       Date:  2014-09-17       Impact factor: 11.528

Review 3.  Acute non-lymphoblastic leukemias in childhood.

Authors:  M G Dole; R P Warrier; L C Yu
Journal:  Indian J Pediatr       Date:  1989 Nov-Dec       Impact factor: 1.967

4.  Terson's syndrome in a patient with acute promyelocytic leukemia on all-trans retinoic acid treatment.

Authors:  A M Abu el-Asrar; A K al-Momen; M S Harakati
Journal:  Doc Ophthalmol       Date:  1993       Impact factor: 2.379

5.  Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid.

Authors:  Jae H Park; Baozhen Qiao; Katherine S Panageas; Maria J Schymura; Joseph G Jurcic; Todd L Rosenblat; Jessica K Altman; Dan Douer; Jacob M Rowe; Martin S Tallman
Journal:  Blood       Date:  2011-06-08       Impact factor: 22.113

6.  Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome.

Authors:  Amit Lahoti; Hagop Kantarjian; Abdulla K Salahudeen; Farhad Ravandi; Jorge E Cortes; Stefan Faderl; Susan O'Brien; William Wierda; Gloria N Mattiuzzi
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

7.  Treatment advances have not improved the early death rate in acute promyelocytic leukemia.

Authors:  James Scott McClellan; Holbrook E Kohrt; Steven Coutre; Jason R Gotlib; Ravindra Majeti; Ash A Alizadeh; Bruno C Medeiros
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

Review 8.  Pathogenesis of disseminated intravascular coagulation in patients with acute promyelocytic leukemia, and its treatment using recombinant human soluble thrombomodulin.

Authors:  Takayuki Ikezoe
Journal:  Int J Hematol       Date:  2013-11-12       Impact factor: 2.490

9.  Clinical aspects of acute myeloid leukemias of the FAB types M3 and M4Eo. The AML Cooperative Group.

Authors:  T Haferlach; W Gassmann; H Löffler; C Jürgensen; J Noak; W D Ludwig; E Thiel; D Haase; C Fonatsch; R Becher
Journal:  Ann Hematol       Date:  1993-04       Impact factor: 3.673

10.  Repeated complete remission in a patient with acute promyelocytic leukemia after treatment with 13-cis-retinoic acid first and with all-trans-retinoic acid in relapse.

Authors:  T Haferlach; H Löffler; B Glass; W Gassmann
Journal:  Clin Investig       Date:  1993-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.